ClinicalTrials.gg
CompletedNCT07128628Updated Jul 14, 2026

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

A Phase 2 interventional study of Lifitegrast/Perfluorohexyloctane Fixed Dose Combination and Lifitegrast in Dry Eye Disease, sponsored by Bausch & Lomb Incorporated. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing lifitegrast in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. lifitegrast · Dry Eye Syndromes.

Enrollment
4th of 22
443 · median 38
Started
2025
with 2 others
Phase 2
2 of 22
none open now
Registered
19th of 22
by date
Lead sponsor
2 of 22
Bausch & Lomb Incorporated

Among the 22 studies testing lifitegrast in Dry Eye Syndromes, this one is the 4th largest by enrollment, is one of 3 that started in 2025, is one of 2 in phase 2, and was the 19th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 22 studies testing lifitegrast in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lifitegrast

lifitegrast: first FDA approval 2016 (XIIDRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing lifitegrast in Dry Eye Syndromes, or all of them as a file.
02

Study summary

A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

This study will include subjects who meet all of the following inclusion criteria:

  • Voluntarily provide written
  • ≥18 years of age
  • Subject-reported history of DED OU for at least 6 months
  • Same eye satisfies the criteria for dry eye signs at both screening and baseline/randomization
  • The criteria for dry eye symptoms are met at both screening and baseline/randomization
  • As needed (PRN) or scheduled use of non-prescription (OTC) artificial tear, gels, or lubricants for symptoms of dry eye within the past 30 days
  • Able and willing to follow instructions, including participation in all trial assessments and visits

Exclusion criteria

Exclusion Criteria:

This study will exclude subjects who meet any of the following exclusion criteria (Note: Ocular exclusion criteria are relevant to both eyes, such that meeting a criterion in either eye excludes the subject from the study):

  • Known allergy or sensitivity to any study treatment (or any of its components)
  • Best-corrected visual acuity (BCVA) of 0.7 logarithm of the minimum angle of resolution (logMAR) or worse (50 Early Treatment Diabetic Retinopathy Study [ETDRS] letters; Snellen equivalent score of 20/100 or worse) at Visit 1 (Screening) or Visit 2 (baseline/randomization)
  • Any (CS) ocular surface slit-lamp findings at Visit 1 (Screening) or Visit 2 (baseline/randomization), or findings that may interfere with trial parameters in the opinion of the Investigator.
  • Use of any of any ocular therapies within 30 days.
  • Unable or unwilling to stop current topical dry eye treatments

Additional criteria per protocol

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
443 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination

  • Active comparator
    Arm 2

    Drug: Lifitegrast

  • Active comparator
    Arm 3

    Drug: Perfluorohexyloctane

  • Placebo comparator
    Arm 4

    Drug: Vehicle

  • Placebo comparator
    Arm 5

    Drug: Vehicle

  • Placebo comparator
    Arm 6

    Drug: Vehicle

Interventions

  • DrugLifitegrast/Perfluorohexyloctane Fixed Dose Combination

    Drug pages: Lifitegrast · Perfluorohexyloctane

    Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks

  • Topical ocular drop of lifitegrast administered for 4 weeks

  • Topical ocular drop of perfluorohexyloctane administered for 4 weeks

  • DrugVehicle

    Topical ocular drop with no active ingredients administered for 4 weeks

  • DrugVehicle

    Topical ocular drop with no active ingredients administered for 4 weeks

  • DrugVehicle

    Topical ocular drop with no active ingredients administered for 4 weeks

06

What researchers measure

Primary outcomes

  1. Total corneal fluorescein staining change from baseline

    Time frame: Baseline, day 29

07

Study locations

32 sites
  • Eye Doctors of Arizona, PLLC
    Phoenix, Arizona 85028, United States
  • Global Research Management, Inc.
    Glendale, California 91204, United States
  • SoCal Eye - Lakewood Clinic
    Long Beach, California 90805, United States
  • LoBue Laser and Eye Medical Center
    Murrieta, California 92562, United States
  • Eye Research Foundation, Inc.
    Newport Beach, California 92663, United States
  • Wolstan and Goldberg Eye Associates
    Torrance, California 90505, United States
  • Segal Drug Trials/Office of Bruce A Segal, MD
    Delray Beach, Florida 33484, United States
  • Bowden Eye and Associates
    Jacksonville, Florida 32256, United States
  • Shettle Eye Research, Inc
    Largo, Florida 33773, United States
  • Clayton Eye Clinical Research, LLC
    Morrow, Georgia 30260, United States
  • Midwest Cornea Associates LLC
    Carmel, Indiana 46032, United States
  • Kannarr Eye Care, LLC
    Pittsburg, Kansas 66762, United States
  • Vance Thompson Vision - Alexandria
    Alexandria, Minnesota 56308, United States
  • Complete Eye Care of Medina
    Medina, Minnesota 55340, United States
  • Insight Eyecare Specialties, Inc.
    Kansas City, Missouri 64111, United States
  • Moyes Eye Center, P.C.
    Kansas City, Missouri 64154, United States
  • Ophthalmology Consultants, Ltd.
    St Louis, Missouri 63131, United States
  • Comprehensive Eye Care Ltd.
    Washington, Missouri 63090, United States
  • Opthalmic consultants of Long Island
    Garden City, New York 11530, United States
  • Rochester Ophthalmological Group,PC
    Rochester, New York 14618, United States
  • Asheville Eye Associates
    Asheville, North Carolina 28803, United States
  • Oculus Research
    Garner, North Carolina 27529, United States
  • CORE Inc.
    Shelby, North Carolina 28150, United States
  • Vance Thompson Vision - Fargo, ND
    West Fargo, North Dakota 58078, United States
  • Insight Research Clinic LLC.
    Powell, Ohio 43065, United States
  • Scott & Christie Eyecare Associates - The Surgery Center at Cranberry
    Cranberry Township, Pennsylvania 16066, United States
  • West Bay Eye Associates
    Warwick, Rhode Island 02888, United States
  • Southern College of Optometry
    Memphis, Tennessee 38104, United States
  • Total Eye Care PA
    Memphis, Tennessee 38119, United States
  • Advancing Vision Research, LLC
    Smyrna, Tennessee 37167, United States
  • Intouch Clinical Research Center
    Houston, Texas 77034, United States
  • Lake Travis Eye and Laser Center
    Lakeway, Texas 78738, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in May 2026, 7 months.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 7 months is close to that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 19, 2025
StartActual
Oct 24, 2025
Primary completionActual
May 28, 2026
CompletionActual
May 28, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07128628
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Oct 24, 2025
Primary completion
May 28, 2026
Completion
May 28, 2026
Last update
Jul 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lifitegrast · Perfluorohexyloctane

Start the discussion